glp-1 shortages news november 2025 Shortage = Over FDA's GLP-1 decision kicks off

Motulsky, H

According to NICE guidance (NG28), the continuation of GLP-1 receptor agonist therapy in type 2 diabetes should be assessed after six months, with treatment continued only if there is a reduction in HbA1c of at least 11 mmol/mol (1%) and, where applicable, a weight loss of at least 3% of initial body weight

Take control of your health and well-being with Set Pointyour partner in effective weight management

The research and development activities are supported by increasing investments and technological advancements

Alcohol may also reduce the medications ability to do its job, making it harder for you to maintain a healthy blood sugar level

Their transparent pricing and acceptance of both insurance and cash payment make ongoing support accessible as you navigate your GLP-1 journey